[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Wueest S, Rapold RA, Schoenle EJ, Konrad D: Fas activation in adipocytes impairs insulin-stimulated glucose uptake by reducing Akt. FEBS Lett; 2010 Oct 8;584(19):4187-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 3T3-L1 adipocytes, activation of Fas by Fas ligand decreased insulin-stimulated glucose uptake, without affecting cell viability.
  • Similarly, insulin-stimulated glucose incorporation and protein levels of Akt were increased in isolated adipocytes from Fas deficient mice when compared to wild-type mice.
  • [MeSH-major] Adipocytes, White / drug effects. Adipocytes, White / metabolism. Antigens, CD95 / metabolism. Glucose / metabolism. Insulin / pharmacology. Proto-Oncogene Proteins c-akt / metabolism
  • [MeSH-minor] 3T3-L1 Cells. Animals. Biological Transport, Active / drug effects. Fas Ligand Protein / metabolism. Fas Ligand Protein / pharmacology. Mice. Mice, Inbred C57BL. Mice, Knockout. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. GLUCOSE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20828573.001).
  • [ISSN] 1873-3468
  • [Journal-full-title] FEBS letters
  • [ISO-abbreviation] FEBS Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Fas Ligand Protein; 0 / Fas protein, mouse; 0 / Fasl protein, mouse; 0 / Insulin; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; IY9XDZ35W2 / Glucose
  •  go-up   go-down


2. Balamurugan S, Sugapriya D, Shanthi P, Thilaka V, Venkatadesilalu S, Pushpa V, Madhavan M: Multidrug resistance 1 gene expression and AgNOR in childhood acute leukemias. Indian J Hematol Blood Transfus; 2007 Dec;23(3-4):73-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidrug resistance 1 gene expression and AgNOR in childhood acute leukemias.
  • The multidrug resistance 1 (MDR1) gene product, P-glycoprotein (Pgp/p170) is a membrane protein, which acts as an ATP dependant efflux pump that expels a wide variety of organic compounds including chemotherapeutic agents from the cell.
  • We have studied MDR1 expression and AgNORS in 41 cases of acute leukemia in children.
  • In this study, AgNOR counts in patients with acute lymphoblastic leukemia (ALL) L2 subtype (FAB classification) were significantly higher as compared to the ALL L1 subtype.
  • Similarly, mean AgNOR count in the acute myeloid Leukemia (AML) M2 subtype was significantly higher as compared to the ALL L1 subtype.
  • However, there was no correlation between AgNOR and treatment outcome or between AgNOR counts and MDR1 expression in any of the subtypes of acute leukemia included in this series.
  • This would suggest that factors other than MDR1 may be of relevance in Pediatric ALL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] Blood. 1992 Jan 15;79(2):295-8 [1346094.001]
  • [Cites] Blood. 1992 Jan 15;79(2):473-6 [1370388.001]
  • [Cites] Br J Haematol. 1991 Jan;77(1):50-3 [1671821.001]
  • [Cites] Am J Pathol. 1996 Apr;148(4):1237-47 [8644864.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1202-10 [12663440.001]
  • [Cites] Oncol Rep. 2004 Dec;12(6):1201-7 [15547738.001]
  • [Cites] J Pathol. 1989 Jul;158(3):185-8 [2475599.001]
  • [Cites] Br J Haematol. 1981 Apr;47(4):553-61 [6938236.001]
  • [Cites] Blood. 1993 May 1;81(9):2394-8 [8097634.001]
  • [Cites] Blood. 1993 Jun 15;81(12):3480-1 [8507883.001]
  • [Cites] Leuk Lymphoma. 1995 Sep;19(1-2):135-40 [8574159.001]
  • [Cites] Cancer Lett. 1996 Nov 12;108(1):87-91 [8950214.001]
  • [Cites] Leukemia. 1997 Oct;11(10):1673-80 [9324288.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1512-8 [9552060.001]
  • [Cites] Am J Hematol. 1999 Jun;61(2):149-52 [10367797.001]
  • [Cites] Leuk Lymphoma. 2002 Feb;43(2):309-14 [11999562.001]
  • [Cites] Mol Cancer Res. 2004 Jun;2(6):339-47 [15235109.001]
  • [Cites] Best Pract Res Clin Haematol. 2004 Dec;17(4):641-51 [15494300.001]
  • (PMID = 23100919.001).
  • [ISSN] 0971-4502
  • [Journal-full-title] Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion
  • [ISO-abbreviation] Indian J Hematol Blood Transfus
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3453125
  • [Keywords] NOTNLM ; Acute leukemia / AgNOR / Multidrug Resistance 1 / P-glycoprotein
  •  go-up   go-down


3. Matsubara K, Yura K: [FISH detected 11q23 microdeletion and translocation at the long arm of chromosome 11 in a child with normal karyotypic acute lymphoblastic leukemia]. Rinsho Ketsueki; 2004 Jan;45(1):61-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [FISH detected 11q23 microdeletion and translocation at the long arm of chromosome 11 in a child with normal karyotypic acute lymphoblastic leukemia].
  • We report on a 6-year-old girl with acute lymphoblastic leukemia (ALL) with 11q23 microdeletion and translocation at the long arm of chromosome 11, which were detected by fluorescence in situ hybridization (FISH) but not by conventional cytogenetics.
  • Bone marrow studies showed 75% of early pre-B lineage lymphoblasts with L1 morphology.
  • However, FISH using mixed lineage leukemia (MLL) and 11q subtelomere probes demonstrated 11q23 microdeletion and translocation at the long arm of chromosome 11 to an undefined chromosome.
  • The patient achieved complete remission 15 days after receiving high-risk group chemotherapy of the Kyoto University Pediatric Hematology/Oncology Study Group and has remained in complete remission for more than 30 months.
  • Since MLL/11q23 abnormalities confer a poor prognosis in childhood ALL, the accurate detection of such abnormalities is of paramount significance in assigning individual cases to risk categories.
  • The findings from the present case and recent literature indicate that the FISH-based approach is complementary to conventional cytogenetics, and should be systematically used in childhood ALL at diagnosis.
  • [MeSH-major] Chromosome Aberrations. Chromosome Deletion. Chromosomes, Human, Pair 11. In Situ Hybridization, Fluorescence. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Drug Administration Schedule. Female. Humans. Remission Induction. Risk

  • Genetic Alliance. consumer health - Chromosome 11.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14999936.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


Advertisement
4. Hafiz MG, Islam A: Extensive skeletal lesions in childhood acute lymphoblastic leukemia. Mymensingh Med J; 2009 Jan;18(1):88-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extensive skeletal lesions in childhood acute lymphoblastic leukemia.
  • Subsequently, he was transfer to Pediatric Hematology and Oncology, Bangabandhu Sheikh Mujib Medical University (BSMMU) for proper management.
  • Bone marrow aspiration findings were suggestive of ALL-L1 and cytochemistry of aspirate showed PAS positive and Sudan black negative.
  • So, an awareness of varied clinical and radiological manifestations of childhood ALL in bone marrow and skeletal system are needed in order to establish a correct diagnosis when the presenting signs and symptoms are enigmatic.


5. Karimi M, Yarmohammadi H, Sabri MR: An analysis of prognostic factors and the five-year survival rate in childhood acute lymphoblastic leukemia. Med Sci Monit; 2002 Dec;8(12):CR792-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An analysis of prognostic factors and the five-year survival rate in childhood acute lymphoblastic leukemia.
  • BACKGROUND: Acute Lymphoblastic Leukemia (ALL) is the most common malignancy in childhood.
  • With newer drug protocols the five-year survival rate is now close to 80%.
  • Two pathologists performed the staging using the morphology method (L1, L2 and L3).
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12503037.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


6. Poyrazoglu S, Gunoz H, Darendeliler F, Bas F, Tutunculer F, Eryilmaz SK, Bundak R, Saka N: Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards. J Pediatr Orthop; 2008 Jun;28(4):483-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Serum calcium, phosphorus, bone turnover markers, L1-L4 areal BMD (aBMD), and fracture rate were evaluated.
  • L1 to L4 aBMD and Z score increased markedly, and fracture rate decreased in all patients during therapy.
  • Mean L1 to L4 aBMD Z scores according to Turkish reference data were higher than that of manufacturer values (P = 0.004).
  • Correction of L1 to L4 vertebrae for bone size yielded to a decrease in osteoporosis in OI patients (41.5% vs 22.3%).
  • [MeSH-major] Bone Density / drug effects. Bone Density Conservation Agents / administration & dosage. Diphosphonates / administration & dosage. Lumbar Vertebrae / radiography. Osteogenesis Imperfecta / drug therapy
  • [MeSH-minor] Adolescent. Anti-Inflammatory Agents. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Infant. Injections, Intravenous. Male. Retrospective Studies. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Osteogenesis imperfecta.
  • MedlinePlus Health Information. consumer health - Bone Density.
  • MedlinePlus Health Information. consumer health - Osteogenesis Imperfecta.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18520289.001).
  • [ISSN] 0271-6798
  • [Journal-full-title] Journal of pediatric orthopedics
  • [ISO-abbreviation] J Pediatr Orthop
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Bone Density Conservation Agents; 0 / Diphosphonates; OYY3447OMC / pamidronate
  •  go-up   go-down


7. Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS: Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J; 2010 Feb;29(2):95-101
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
  • BACKGROUND: We describe the safety of the human papillomavirus (HPV)-6/11/16/18 vaccine using updated clinical trial data (median follow-up time of 3.6 years) and summarize up to 3 years of post-licensure surveillance.
  • METHODS: In 5 clinical trials, 21,480 girls/women aged 9 to 26 years and boys aged 9 to 16 years received >or=1 dose of HPV-6/11/16/18 vaccine or placebo.
  • As of June 2009, >25 million doses of HPV-6/11/16/18 vaccine had been distributed in the United States with >50 million doses globally.
  • Post-licensure safety as summarized by the Centers for Disease Control and Prevention using the United States Vaccine Adverse Event Reporting System database is also reported.
  • RESULTS: Eight subjects experienced a treatment-related serious AE (0.05% vaccine; 0.02% placebo).
  • Of 18 deaths (0.1% vaccine; 0.1% placebo), all were considered unrelated to study treatment.
  • New medical conditions which were potentially consistent with autoimmune phenomena were reported in 2.4% of both vaccine and placebo recipients.
  • Pain, the most common injection-site AE, occurred more frequently with vaccine (81% vaccine; 75% placeboaluminum; 45% placebo-saline).
  • The Vaccine Adverse Event Reporting System has received 14,072 reports for the HPV-6/11/16/18 vaccine since licensure, with only 7% being serious AEs, about half the average reported for licensed vaccines in general.
  • [MeSH-major] Papillomavirus Infections / prevention & control. Papillomavirus Vaccines / adverse effects. Papillomavirus Vaccines / immunology
  • [MeSH-minor] Adolescent. Adult. Child. Drug-Related Side Effects and Adverse Reactions. Female. Fever. Headache. Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18. Humans. Incidence. Male. Pain. Placebos / administration & dosage. Product Surveillance, Postmarketing. United States. Vaccines, Virosome / adverse effects. Vaccines, Virosome / immunology. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19952863.001).
  • [ISSN] 1532-0987
  • [Journal-full-title] The Pediatric infectious disease journal
  • [ISO-abbreviation] Pediatr. Infect. Dis. J.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; 0 / Papillomavirus Vaccines; 0 / Placebos; 0 / Vaccines, Virosome
  •  go-up   go-down


8. Carroccio A, Iacono G, Cottone M, Di Prima L, Cartabellotta F, Cavataio F, Scalici C, Montalto G, Di Fede G, Rini G, Notarbartolo A, Averna MR: Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children. Clin Chem; 2003 Jun;49(6 Pt 1):861-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of fecal calprotectin assay in distinguishing organic causes of chronic diarrhea from irritable bowel syndrome: a prospective study in adults and children.
  • We evaluated the diagnostic accuracy of a FC assay in identifying "organic" causes of chronic diarrhea in consecutive adults and children.
  • False-positive results (8 of 40 cases) were associated with the use of aspirin (3 cases) or nonsteroidal antiinflammatory drugs (1 case) and with the presence of concomitant liver cirrhosis (3 cases).
  • In pediatric patients, sensitivity was 70%, specificity was 93%, and positive and negative predictive values were 96% and 56%.
  • In adults, false negatives occur (e.g., in celiac disease) and false-positive results are seen in cirrhosis or users of nonsteroidal antiinflammatory drugs.
  • Diagnostic accuracy is higher in children.
  • [MeSH-major] Colonic Diseases, Functional / diagnosis. Diarrhea / diagnosis. Feces / chemistry. Leukocyte L1 Antigen Complex / analysis


9. Chou IJ, Lin KL, Wang HS, Wang CJ: Evaluation of bone mineral density in children receiving carbamazepine or valproate monotherapy. Acta Paediatr Taiwan; 2007 Nov-Dec;48(6):317-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Antiepileptic drugs have been shown to be associated with a lowering of bone mineral density in childhood and adolescence, which are critical periods of skeletal mineralization.
  • Lumbar bone mineral density of L1 to L4 was measured by dual-energy X-ray absorptiometry.
  • Four (57%) patients in the 7 carbamazepine-treated children with Z-score of -1.5 or lower had serum drug level lower than therapeutic range.
  • [MeSH-major] Anticonvulsants / adverse effects. Bone Density / drug effects. Carbamazepine / adverse effects. Valproic Acid / adverse effects
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Epilepsy / drug therapy. Female. Humans. Male. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Density.
  • Hazardous Substances Data Bank. CARBAMAZEPINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18437965.001).
  • [ISSN] 1608-8115
  • [Journal-full-title] Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi
  • [ISO-abbreviation] Acta Paediatr Taiwan
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Anticonvulsants; 33CM23913M / Carbamazepine; 614OI1Z5WI / Valproic Acid
  •  go-up   go-down


10. MacDonald KD, McKenzie KR, Henderson MJ, Hawkins CE, Vij N, Zeitlin PL: Lubiprostone activates non-CFTR-dependent respiratory epithelial chloride secretion in cystic fibrosis mice. Am J Physiol Lung Cell Mol Physiol; 2008 Nov;295(5):L933-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The magnitude of the NPD response to 20 muM lubiprostone was -5.8 +/- 2.1 mV (CF, n = 12), -8.1 +/- 2.6 mV (C57Bl/6 wild-type, n = 12), and -5.3 +/- 1.2 mV (AJ wild-type, n = 8).

  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pflugers Arch. 2000 Jun;440(2):193-201 [10898518.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Aug;295(2):G234-51 [18511742.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Nov;281(5):L1173-9 [11597909.001]
  • [Cites] EMBO Rep. 2001 Nov;2(11):1047-51 [11606421.001]
  • [Cites] Hum Mol Genet. 2002 Jan 15;11(2):125-31 [11809721.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Apr;282(4):C805-16 [11880269.001]
  • [Cites] J Biol Chem. 2002 Jun 28;277(26):23604-11 [11976342.001]
  • [Cites] Pflugers Arch. 2003 Jan;445(4):504-12 [12548397.001]
  • [Cites] Nat Genet. 2003 Apr;33(4):527-32 [12612585.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Nov;287(5):C1173-83 [15213059.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2004 Nov;287(5):L936-43 [15246976.001]
  • [Cites] Nature. 1992 Mar 5;356(6364):57-60 [1311421.001]
  • [Cites] Am J Physiol. 1992 Jul;263(1 Pt 1):L1-14 [1322048.001]
  • [Cites] Hum Mol Genet. 1993 Mar;2(3):219-24 [7684640.001]
  • [Cites] Am J Physiol. 1994 May;266(5 Pt 1):C1478-83 [7515571.001]
  • [Cites] Science. 1994 Dec 9;266(5191):1705-8 [7527588.001]
  • [Cites] Am J Respir Cell Mol Biol. 1995 Jun;12(6):597-604 [7766424.001]
  • [Cites] Am J Physiol. 1996 Nov;271(5 Pt 1):L829-37 [8944727.001]
  • [Cites] Eur Respir J. 1997 Oct;10(10):2194-7 [9387939.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3879-84 [9520461.001]
  • [Cites] J Membr Biol. 2004 Nov;202(1):21-37 [15702377.001]
  • [Cites] J Cell Sci. 2005 Sep 15;118(Pt 18):4243-52 [16155254.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):31587-94 [16027156.001]
  • [Cites] Pediatr Pulmonol. 2006 Feb;41(2):151-7 [16369925.001]
  • [Cites] N Engl J Med. 2006 Jan 19;354(3):241-50 [16421365.001]
  • [Cites] J Membr Biol. 2005 Nov;208(1):65-76 [16596447.001]
  • [Cites] Paediatr Drugs. 2007;9(1):1-10 [17291132.001]
  • [Cites] J Clin Gastroenterol. 2007 Apr;41(4):345-51 [17413599.001]
  • [Cites] Br J Pharmacol. 2007 Apr;150(8):1055-65 [17339840.001]
  • [Cites] Am J Gastroenterol. 2008 Jan;103(1):170-7 [17916109.001]
  • [Cites] Am J Physiol Cell Physiol. 2001 Jul;281(1):C46-54 [11401826.001]
  • (PMID = 18805957.001).
  • [ISSN] 1040-0605
  • [Journal-full-title] American journal of physiology. Lung cellular and molecular physiology
  • [ISO-abbreviation] Am. J. Physiol. Lung Cell Mol. Physiol.
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / R01 HL 59410; United States / NHLBI NIH HHS / HL / T32 HL 72748
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chloride Channels; 0 / Chlorides; 0 / ClC-2 chloride channels; 0 / RNA, Messenger; 126880-72-6 / Cystic Fibrosis Transmembrane Conductance Regulator; 7662KG2R6K / Lubiprostone; 8L70Q75FXE / Adenosine Triphosphate; F5TD010360 / Alprostadil
  • [Other-IDs] NLM/ PMC2584880
  •  go-up   go-down


11. Fagerberg UL, Lööf L, Merzoug RD, Hansson LO, Finkel Y: Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr; 2003 Oct;37(4):468-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A health questionnaire was used to ensure that these children fulfilled the inclusion criterion and did not have intercurrent disease, nasal or menstrual bleeding, or nonsteroidal anti-inflammatory drug medication before the sampling period.
  • [MeSH-major] Feces / chemistry. Leukocyte L1 Antigen Complex / analysis

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14508218.001).
  • [ISSN] 0277-2116
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leukocyte L1 Antigen Complex
  •  go-up   go-down


12. Turner D, Leach ST, Mack D, Uusoue K, McLernon R, Hyams J, Leleiko N, Walters TD, Crandall W, Markowitz J, Otley AR, Griffiths AM, Day AS: Faecal calprotectin, lactoferrin, M2-pyruvate kinase and S100A12 in severe ulcerative colitis: a prospective multicentre comparison of predicting outcomes and monitoring response. Gut; 2010 Sep;59(9):1207-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Stool samples from 101 children (13.3 + or - 3.6 years; Pediatric UC Activity Index (PUCAI) at admission 72 + or - 12 points) were obtained at the third day of intravenous steroid therapy.
  • Predictive validity was assessed using diagnostic utility statistics to predict steroid failure (ie, the need for salvage treatment).
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Monitoring / methods. Epidemiologic Methods. Glucocorticoids / therapeutic use. Humans. Lactoferrin / metabolism. Leukocyte L1 Antigen Complex / metabolism. Prognosis. Pyruvate Kinase / metabolism. S100 Proteins / metabolism. S100A12 Protein. Treatment Outcome

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20801771.001).
  • [ISSN] 1468-3288
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Glucocorticoids; 0 / Leukocyte L1 Antigen Complex; 0 / S100 Proteins; 0 / S100A12 Protein; 0 / S100A12 protein, human; EC 2.7.1.40 / Pyruvate Kinase; EC 3.4.21.- / Lactoferrin
  •  go-up   go-down


13. Choma T, Burke M, Kim C, Kakarlapudi R: Epidural abscess as a delayed complication of spinal instrumentation in scoliosis surgery: a case of progressive neurologic dysfunction with complete recovery. Spine (Phila Pa 1976); 2008 Feb 1;33(3):E76-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is exceedingly uncommon in the pediatric population.
  • Deep wound infection after adolescent idiopathic scoliosis surgery is a well-known entity that has been reported in several studies; however, we could find no documented incidences of epidural abscess resulting from adolescent idiopathic scoliosis surgery in the pediatric population.
  • Her postoperative course was complicated by acute wound infection that underwent irrigation and debridement with retention of implants.
  • RESULTS: After magnetic resonance imaging confirmation of a T5 to T10 epidural mass, the patient underwent debridement through her fusion mass from T5 to L1.
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / administration & dosage. Anti-Inflammatory Agents / administration & dosage. Combined Modality Therapy. Debridement. Female. Humans. Methylprednisolone Hemisuccinate / administration & dosage. Paraplegia / drug therapy. Paraplegia / etiology. Paraplegia / radiography. Recovery of Function. Time Factors

  • Genetic Alliance. consumer health - Scoliosis.
  • MedlinePlus Health Information. consumer health - Scoliosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18303449.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Anti-Inflammatory Agents; 5GMR90S4KN / Methylprednisolone Hemisuccinate
  •  go-up   go-down






Advertisement